CN102836186B - Tibetan medicine for treating haemorrhoids and preparation method thereof - Google Patents
Tibetan medicine for treating haemorrhoids and preparation method thereof Download PDFInfo
- Publication number
- CN102836186B CN102836186B CN 201210342208 CN201210342208A CN102836186B CN 102836186 B CN102836186 B CN 102836186B CN 201210342208 CN201210342208 CN 201210342208 CN 201210342208 A CN201210342208 A CN 201210342208A CN 102836186 B CN102836186 B CN 102836186B
- Authority
- CN
- China
- Prior art keywords
- tibetan medicine
- active component
- group
- present
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a Tibetan medicine for treating haemorrhoids, which is made up of an active component or the active component and the pharmaceutically acceptable adjuvants. The active component is prepared by fructus chebulae, female cattle urea, embelia laeta, honey and zogta according to a certain weight ratio, and can be prepared into dose. The Tibetan medicine provided by the invention has the effects on Yama trichomonacida, antiphlogosis and promoting blood circulation to remove blood stasis. The Tibetan medicine can be utilized to treat haemorrhoids, slight pain, stabbing pain, causalgia, swelling pain, bleeding and itching on the anus and crissal skin, and bleeding while defecating and crissal ache and the like.
Description
Technical field
The present invention relates to a kind of Tibetan medicine for the treatment of hemorrhoid and preparation method thereof.
Background technology
Hemorrhoid are commonly encountered diseases clinically, frequently-occurring disease, take hemorrhage, deviate from, pain etc. is as cardinal symptom.Along with living standard improves, activity reduces, and hemorrhoid patients is more and more.Therapeutic Method is a lot, but because anal canal and skin around the rectum paraesthesia are sharp, comparatively responsive to pain.At present a lot of scholars trend towards for the treatment of hemorrhoid: need not treat asymptomatic hemorrhoid, Symptomatic hemorrhoid according to state of an illness system of selection, are mainly contained operation and non-operative treatment two large classes.
Although the medicine for the treatment of hemorrhoid is a lot of at present, curative effect still can not be satisfactory.Therefore, there is tight demand in people's Tibetan medicinal preparation that curative effect is better treated hemorrhoid.
Up to now, also do not find the report of any relevant Tibetan medicinal composition of the present invention.The inventor is through repeatedly research, and the repeatedly checking by animal and clinical trial, has finally found the Tibetan medicine oral drugs that the treatment of better curative effect hemorrhoid are arranged, thereby has finished the present invention.
Summary of the invention
The object of the invention just provides a kind of Tibetan medicine of more effectively treating hemorrhoid.
Another object of the present invention has provided the preparation method of this Tibetan medicine.
The present invention is a kind of Tibetan medicine, is formed or is comprised of active component and pharmaceutically acceptable adjuvant by active component, and wherein said active component is to be made by following bulk drugs: Fructus Chebulae, HUANGMU cattle urine, Fructus embeliae laetae, Mel, ZUOTAI.
It has selected Fructus Chebulae, HUANGMU cattle urine, Fructus embeliae laetae, Mel, ZUOTAI to make up as raw material, and wherein (1) Fructus Chebulae is the dry mature fruit of Combretum Racemosum plant Fructus Chebulae Terminalia chebula Retz..Puckery, property is flat; Return lung, large intestine channel; Have nourishing and take care of health, rise stomach-fire, aid digestion, comfortable, the function that makes eye bright; Cure mainly the disease that " dragon ", " red bar ", " Baconic " bring out; Have the pharmacological actions such as convergence, antidiarrheal, resisting pathogenic microbes, spasmolytic.(2) Fructus embeliae laetae is the dry mature fruit of Myrsinacea leaves of plants Fructus embeliae laetae Embelia oblongifolia Hemsl..Nature and flavor are hot, temperature, sharp.Have parasite killing, promote the effect of stomach temperature.Be used for taeniasis, edema.Cure mainly raw property or lymphatic temperament disease, Enterozoa, raw sexual trauma, dyspepsia, dental caries pain, arthralgia, constipation.Have the extremely pharmacological actions such as Enterozoa, antifertility, promotion wound healing.(3) Mel is the honey that Apidae insecticide apis cerana Apis cerana Fabricius or apis mellifera Linnaeus Apis mellifera Linnaeus make.Wound surface there are convergence, nutrition and promotion Healing, have lubricity to eliminate the phlegm and laxative effective, sweet in the mouth, property is flat; Return spleen, stomach, lung, large intestine channel.Has harmonizing the spleen and stomach, relieving spasm to stop pain, nourishing the lung to arrest cough, loosening bowel to relieve constipation, skin moistening granulation promoting, the effect of detoxifcation.Cure mainly the empty pain of gastral cavity abdomen, xeropulmonary cough, dryness of the intestine constipation, conjunctival congestion, aphtha, ulcer being unable to heal, rubella pruritus, burn due to hot liquid or fire, rhagadia manus et pedis etc.(4) ZUOTAI is the abbreviation of Tibetan language " the blue or green Europe Qu Zuozhu of core admires wooden ", translate again " assistant platform " (defending Tibetan, Anduo County's language), " zota " (Kang Bayu), it is the main intermediate raw material of producing famous and precious Tibetan medicines such as " 70 flavor Pearl Pills ", the process of preparing Chinese medicine of Tibetan medicine " ZUOTAI " needs about 2 months, mainly washes poison, eight gold medals, eight ore deposit cinerations and hydrargyrum by hydrargyrum and closes refining three parts and form.The Preparation process product that the hydrargyrum of producing for native mercury or cinnabar ore deposit is made jointly through the product of reprocessabilty detoxification and the ash that closes malicious eight metals add the black powder of 60 multiple auxiliary materials such as eight bronzes, Bayuan powder, three sour waters and hydrargyrum formation after concocting in concocting process.Puckery, property is flat.Effect with medicament curative effect enhancement, granulation promoting spleen invigorating, strengthening by means of tonics, disease-resistant body-building.Cure mainly apoplexy, leprosy, painful abdominal mass tumor, anthrax, gout, grasserie, various inflammation, various nosotoxicosiss, and " Baconic " disease, hypertension, heart disease, cold, that heat causes all diseases, crazy disease; Take without the patient and to have nourishing and fit keeping function, diseases prevention, life lengthening, slow down aging strengthens the special efficacies such as face function and skin gloss; With other any medicine compatibilities, has the raising curative effect, the effect such as prolong drug holding time in vivo.(5) HUANGMU cattle urine is the urine of bovid cattle Bos taurus domesticus Gmelin. cow.Salty in the mouth, hardship, cool in nature.Have " Ya Ma " parasite killing, detumescence, the effect of yellow fluid, blood circulation promoting and blood stasis dispelling clearly.These drug regimens are used so that each efficacy of drugs produces synergism, thereby can effectively treat hemorrhoid.
The consumption of Tibetan medicine component of the present invention is also groped to sum up to draw through the inventor in a large number, and each crude drug consumption is for all to have good therapeutic effect in the following weight parts scope:
Fructus Chebulae 150～600g, HUANGMU cattle urine 250～1000g, Fructus embeliae laetae 50～220g, Mel 40～170g, ZUOTAI 1～6g.
Be preferably: Fructus Chebulae 300g, HUANGMU cattle urine 500g, Fructus embeliae laetae 110g, Mel 87g, ZUOTAI 3g.
The preparation of Tibetan medicine active component of the present invention can be the crude drug convection drying of above-mentioned consumption to be pulverized make; Also the crude drug of above-mentioned consumption can be adopted the conventional method of Chinese medicine preparation such as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs " the 73rd～74 page, Science and Technology of Shanghai publishing house publishes in November, 1986) to make.
The active component of Tibetan medicine of the present invention can add various conventional adjuvant required when preparing different dosage form, such as disintegrating agent, lubricant, binding agent etc. with the method for Chinese medicinal of routine (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs ", Science and Technology of Shanghai publishing house publishes in November, 1986) be prepared into any peroral dosage form commonly used, such as powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has " Ya Ma " parasite killing, antiinflammatory, the effect of blood circulation promoting and blood stasis dispelling.Be used for hemorrhoid, mild pain, twinge, causalgia, distending pain, anus and the hemorrhage pruritus of crissum skin, hemorrhage and crissum pain etc. during stool.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 1.2～2g, 2～3 times on the one.
[specific embodiment]
Come by the following examples further to set forth the preparation method of Tibetan medicine of the present invention.
The powder preparation of [embodiment 1] Tibetan medicine of the present invention:
Take by weighing Fructus Chebulae 300g, HUANGMU cattle urine 500g, Fructus embeliae laetae 110g, Mel 87g, ZUOTAI 3g, HUANGMU cattle urine decocts the elimination slag, and filtrate is condensed into paste, then adds Fructus Chebulae and the suitable quantity of water of enucleation, continuing heating decocts to liquid closely dried, add again refining good Mel, Fructus embeliae laetae powder and ZUOTAI, stir, dry below 60 ℃, be ground into fine powder, mixing, packing namely gets powder.
The pill preparation of [embodiment 2] Tibetan medicine of the present invention:
Take by weighing Fructus Chebulae 150g, HUANGMU cattle urine 250g, Fructus embeliae laetae 220g, Mel 124g, ZUOTAI 6g, HUANGMU cattle urine decocts the elimination slag, and filtrate is condensed into paste, then the Fructus Chebulae and the suitable quantity of water that add enucleation, the continuation heating decocts to liquid closely dried, adds refining good Mel, Fructus embeliae laetae powder and ZUOTAI again, stir, dry below 60 ℃, be ground into fine powder, mixing, use water pill, dry below 60 ℃, polishing, packing namely gets pill.
The granule preparation of [embodiment 3] Tibetan medicine of the present invention:
Take by weighing Fructus Chebulae 600g, HUANGMU cattle urine 1000g, Fructus embeliae laetae 50g, Mel 40g, ZUOTAI 1g, HUANGMU cattle urine decocts the elimination slag, and filtrate is condensed into paste, then the Fructus Chebulae and the suitable quantity of water that add enucleation, the continuation heating decocts to liquid closely dried, adds refining good Mel, Fructus embeliae laetae powder and ZUOTAI again, stir, dry below 60 ℃, be ground into fine powder, mixing, add the adjuvant granulation, dry below 60 ℃, granulate, packing namely gets granule.
The capsule preparation of [embodiment 1] Tibetan medicine of the present invention:
Take by weighing Fructus Chebulae 200g, HUANGMU cattle urine 600g, Fructus embeliae laetae 200g, Mel 98g, ZUOTAI 2g, HUANGMU cattle urine decocts the elimination slag, and filtrate is condensed into paste, then adds Fructus Chebulae and the suitable quantity of water of enucleation, continuing heating decocts to liquid closely dried, add again refining good Mel, Fructus embeliae laetae powder and ZUOTAI, stir, dry below 60 ℃, be ground into fine powder, mixing, the gelatine capsule of packing into namely gets capsule.
The tablet preparation of [embodiment 5] Tibetan medicine of the present invention:
Take by weighing Fructus Chebulae 400g, HUANGMU cattle urine 900g, Fructus embeliae laetae 60g, Mel 46g, ZUOTAI 4g, HUANGMU cattle urine decocts the elimination slag, and filtrate is condensed into paste, then the Fructus Chebulae and the suitable quantity of water that add enucleation, the continuation heating decocts to liquid closely dried, adds refining good Mel, Fructus embeliae laetae powder and ZUOTAI again, stir, dry below 60 ℃, be ground into fine powder, mixing, add the adjuvant granulation, dry below 60 ℃, granulate, tabletting namely gets tablet.
Below further set forth the beneficial effect of Tibetan medicine of the present invention by test example, these test examples have comprised pharmacodynamics test and the clinical observation on the therapeutic effect test of Tibetan medicine embodiment 1 of the present invention.
The tests such as the hemostasis of [test example 1] Tibetan medicine embodiment 1 of the present invention, analgesic activity:
Test material: anthology invention Tibetan medicine embodiment 1; Aspirin tablet, lot number: 20100407, produced by Changbaishan Pharmacy Co., Ltd; Yunnan Baiyao Capsule, lot number: 20100111, produced by Yunnan Baiyao Group Wuxi Medicine Co., Ltd.; 20106012), APTT is provided by test kit (lot number: 20105723) provide by French STAGO-R company reagent and instrument PT measure test kit (lot number:; Adenosine diphosphate (ADP) disodium (ADP, Shanghai Bai Ao Bioisystech Co., Ltd, lot number: 20070508); Glacial acetic acid; Filter paper; Stopwatch; Microscope slide; Rat calcitonin-gene-related peptide (CGRP) ELISA test kit is available from west, Shanghai Tang bio tech ltd; The full-automatic coagulo meter of France STAGO-R; Chrono-log 560vs platelet aggregation instrument.Kunming mouse, SD rat are provided by Qinghai Province's Experimental Animal Center.
Experimental technique: 1, the impact of, clotting time hemorrhage on the SD rat: get 50 of SD rats, be divided at random 5 groups, 10 every group, namely the blank group is given the isometric(al) distilled water; Positive controls is given Yunnan Baiyao Capsule 0.5g/kg.d
-lTibetan medicine embodiment 1(6g of the present invention, 3g, 1.5g crude drug/kg.d
-l) high, medium and low dosage group.Sub-cage rearing, each organizes equal gastric infusion, and 1 time/d, continuous 7d.12h after the last administration fixedly cuts tail 5cm with rat, clocks immediately, sucks drop of blood every 30s with filter paper, is the bleeding time till no longer hemorrhage.Other gets 50 of SD rats, and grouping and administering mode are the same, and 12h after the last administration fixes rat, plucks a branch hole ball and gets blood, and each one is bled in the two ends of microscope slide, and drop of blood diameter 5mm clocks with stopwatch immediately.Stir gently inwards 1 time from the drop of blood edge with the cleaning pin every 30s, and observation has or not the blood streak to provoke.Ending to provoking the blood streak from the blood sampling beginning, is clotting time between institute lasts.Another is bled and reviews for last, the record clotting time.The results are shown in Table 1.
2, Tibetan medicine embodiment 1 of the present invention is on the PT of SD rat, the impact of APTT: get 50 of SD rats, grouping and administering mode are with under 1.12h after the last administration, (0.4～0.6ml/100g) intraperitoneal injection of anesthesia rat is opened the abdominal cavity, from abdominal aortic blood 2.7mL with 10% chloral hydrate, put in vitro (ratio of blood and sodium citrate is 9: 1) that be added with 3.8% liquor sodii citratis, behind the mixing with 3000rmin
-1Centrifugal 10min obtains anemia platelet (PPP) blood plasma, then adopts application of automated coagulation analyzer to measure PT, APTT.The results are shown in Table 2.
3, Tibetan medicine embodiment 1 of the present invention is on the impact of the platelet aggregation rate of SD rat: get 50 of SD rats, grouping, administering mode and blood sampling are all with under 2.Behind the mixing with 1000rmin
-1Centrifugal 15min gets upper strata platelet rich plasma (PRP) 450 μ l, and remainder continues with 3000rmin
-1Centrifugal 10min, separate anemia platelet (PPP) blood plasma, zeroing adds derivant 3.33 μ mol/LADP 40 μ l in platelet rich plasma (PRP) take platelet poor plasma (PPP) as control tube, measures the platelet aggregation degree by turbidimetry in the blood pool instrument.The results are shown in Table 3.
4, Tibetan medicine embodiment 1 of the present invention affects the hot plate method in mice analgesic: because the male mice scrotum that is heated touches hot plate, spurious results can occur, so female mice is adopted in experiment.The regulation thermostat water temperature is put into the 500ml beaker wherein to (55.0 ± 0.5) ℃, makes the beaker bottom contact water surface.Get 1 of Kunming kind female mice at every turn, put into beaker.Record is from putting into beaker to occurring licking rear foot required time (s), as the pain threshold of this Mus.Allly lick the metapedes time and give it up less than 5s or greater than 30s or leaper.Interval 1h, its normal pain threshold of replication is got two subnormal threshold of pain meansigma methodss, as the Basic Pain Threshold value before the administration of this Mus, is no more than 30s as qualified take meansigma methods.Qualified mice is divided into 5 groups at random, and 10 every group, namely the blank group is given the isometric(al) distilled water; Positive controls is given aspirin tablet 0.6g/kg.d
-lTibetan medicine embodiment 1(6g of the present invention, 3g, 1.5g crude drug/kg.d
-l) high, medium and low dosage group.Sub-cage rearing, each organizes equal gastric infusion, and 1 time/d, continuous 7d.6h respectively measures the pain threshold of mice after administration in the 7th day.Mice takes off it rapidly after the foot reaction occurring licking, in order to avoid scald.If 60s is still reactionless, to take out immediately, its threshold of pain is pressed 60s and is calculated.Sufficient time difference (pain threshold) of reacting occurs licking as observation index take mice, calculate the medicine analgesic percentage rate.The results are shown in Table 4.
5, Tibetan medicine embodiment 1 of the present invention affects mice acetic acid twisting method analgesic: laboratory animal, grouping, administration are with under 4.Sub-cage rearing, each organizes equal gastric infusion, and 1 time/d, continuous 7d.6h after administration in the 7th day, the acetum with 0.6% is pressed the dosage of 0.1ml/10g, lumbar injection.Giving behind the acetic acid in the 15min, it is observation index that writhing (abdominal part indent, stretch hind leg, buttocks is raised) number of times appears in each tested mice, calculates the writhing response frequency.The results are shown in Table 5.
6,1 couple of rat plasma CGRP of Tibetan medicine embodiment of the present invention level determination result: get 50 of SD rats, grouping and administering mode are with under 1.12h after the last administration, with 10% chloral hydrate (0.4～0.6ml/100g) anesthetized rat, from abdominal aortic blood 5ml, inject the test tube of EDTA-2Na (1g/L) and aprotinin (50mU/L), shake up, 4 ℃, the centrifugal 10min of 3000r/min isolates 1 part of blood plasma, put-70 ℃ of cryogenic refrigerators and preserve CGRP value to be measured.The results are shown in Table 6.
Experimental result: 1, Tibetan medicine embodiment 1 of the present invention sees Table 1 to the impact in rat blood coagulation, bleeding time.
Table 1 Tibetan medicine embodiment 1 of the present invention is on the impact (x ± s, n=10) in rat blood coagulation, bleeding time
Group number of animals dosage (g/kg) clotting time (s) bleeding time (s)
Blank group 10 122.70 ± 14.46
★ ★ ▲ ▲438.6 ± 71.31
★ ★ ▲ ▲
Positive controls 10 0.5 85.3 ± 11.47
*153.1 ± 59.82
*
Low dose group 10 1.5 87.8 ± 13.51
*236.6 ± 88.66
*
Middle dosage group 10 3 69.2 ± 10.76
* ▲147.4 ± 43.02
*
High dose group 10 6 45.50 ± 10.08
* ★ ★ ▲ ▲107.7 ± 23.9
* ▲
Illustrate: compare with the blank group:
*P＜0.01; Compare with positive controls:
★ ★P＜0.01,
★P＜0.05; Compare with low dose group:
▲ ▲P＜0.01,
▲P＜0.05.
As seen from Table 1: during the clotting time of affecting of the blood coagulation of SD rat, bleeding time Tibetan medicine embodiment of the present invention 1 heavy dose of group is significantly shorter than, small dose group, positive controls and blank group (P＜0.01), low dose group and positive controls there was no significant difference (P〉0.05); The bleeding time of Tibetan medicine embodiment 1 high dose group of the present invention is significantly shorter than low dose group and blank group (P＜0.05), with middle dosage group and positive controls there was no significant difference (P〉0.05).
2, Tibetan medicine embodiment 1 of the present invention sees Table 2 to the impact of P of Rats T, APTT.
Table 2 Tibetan medicine embodiment 1 of the present invention is on the impact (x ± s, n=10) of P of Rats T, APTT
Group number of animals dosage (g/kg) PT/s APTT/s
Blank group 10 21.77 ± 2.81
▲ ▲24.55 ± 2.18
▲
Positive controls 10 0.5 17.32 ± 1.35
*20.30 ± 1.68
*
Low dose group 10 1.5 17.45 ± 1.67
* ★21.03 ± 2.35
* ★
Middle dosage group 10 3 15.70 ± 1.40
* ★17.89 ± 1.34
* ▲
High dose group 10 6 17.19 ± 1.29
* ★18.68 ± 0.85
* ★
Illustrate: compare with vehicle group:
*P＜0.01; With the YUNNAN BAIYAO group:
★P〉0.05; Compare with small dose group:
▲P＜0.05.
As seen from Table 2: the PT that affects Tibetan medicine embodiment 1 each dosage group of the present invention, APTT time on PT, the APTT of SD rat all are significantly shorter than blank group (P＜0.01), with positive controls there was no significant difference (P〉0.05).
3, Tibetan medicine embodiment 1 of the present invention sees Table 3 to the impact of rat platelet aggregation rate.
Table 3 Tibetan medicine embodiment 1 of the present invention is on the impact (x ± s, n=10) of rat platelet aggregation rate
Group number of animals dosage (g/kg) ADP (maximum agglutination rate)
Blank group 10 46.7 ± 10.0
Positive controls 10 0.5 78.4 ± 12.5
*
Low dose group 10 1.5 62.2 ± 11.3
* ★
Middle dosage group 10 3 80.8 ± 10.5
* ★ ▲
High dose group 10 6 61.4 ± 12.5
* ★
Illustrate: compare with the blank group:
*P＜0.05,
*P＜0.01; Compare with positive controls:
★P〉0.05; Compare with low dose group:
▲P＜0.05.
As seen from Table 3: on the platelet aggregation rate that affects dosage group among the Tibetan medicine embodiment 1 of the present invention of the platelet aggregation rate of SD rat apparently higher than high and low dose group and blank group (P＜0.05), with positive controls there was no significant difference (P〉0. 05).
4,1 pair of hot plate method in mice analgesic effect of Tibetan medicine embodiment of the present invention sees Table 4.
1 pair of hot plate method in mice analgesic effect of table 4 Tibetan medicine embodiment of the present invention (x ± s, n=10)
(s) rate elongation (%) behind (s) 6h before group number of animals dosage (g/kg) medication
Blank group 10 12.38 ± 4.31 12.16 ± 4.54
★ ▲ ▲
Positive controls 10 0.6 11.61 ± 4.29 21.48 ± 5.65
*85.01
Low dose group 10 1.5 11.70 ± 3.93 20.77 ± 4.10
*77.52
Middle dosage group 10 3 11.64 ± 4.25 21.40 ± 4.41
*83.85
High dose group 10 6 11.34 ± 3.63 22.62 ± 7.38
*99.47
Illustrate: compare with the blank group:
*P＜0.01; Compare with positive controls:
★ ★P＜0.01; Compare with low dose group:
▲ ▲P＜0.01.
As seen from Table 4: the hot plate method in mice analgesic is affected Tibetan medicine embodiment 1 each dosage group of the present invention and the comparison of blank group, can obviously improve the hot plate method in mice pain threshold, significant difference (P＜0.01) is all arranged; Positive controls is compared with Tibetan medicine embodiment 1 each dosage group of the present invention, and no significant difference (P〉0.05), point out it to improve hot plate method in mice pain threshold effect suitable; Tibetan medicine embodiment 1 each dosage group analgesia rate of the present invention and dosage are linear, during high dose is better than, low dose group; The dosage group is suitable among positive controls analgesia rate and the Tibetan medicine embodiment 1 of the present invention.
5, the effect of 1 pair of mice method of acetic acid of Tibetan medicine embodiment of the present invention analgesic sees Table 5.
1 pair of mice method of acetic acid of table 5 Tibetan medicine embodiment of the present invention analgesic effect (x ± s, n=10)
Writhing number of times in group number of animals dosage (g/kg) 15min
Blank group 10 28.60 ± 7.02
★ ★ ▲ ▲
Positive controls 10 0.6 12.90 ± 6.49
*
Low dose group 10 1.5 15.70 ± 6.96
*
Middle dosage group 10 3 14.30 ± 5.10
*
High dose group 10 6 7.00 ± 3.89
* ▲
Illustrate: compare with the blank group:
*P＜0.01; Compare with positive controls:
★ ★P＜0.01; Compare with low dose group:
▲ ▲P＜0.01,
▲P＜0.05.
As seen from Table 5: mice acetic acid twisting method analgesic is affected Tibetan medicine embodiment 1 each dosage group of the present invention and the comparison of blank group, can significantly reduce mouse writhing frequency (P＜0.01); Positive controls is compared with Tibetan medicine embodiment 1 each dosage group of the present invention, and no significant difference (P〉0.05), point out it to reduce mouse writhing frequency effect suitable; Tibetan medicine embodiment of the present invention 1 each dosage group reduce writhing frequency and dosage linear, during high dose is better than, low dose group.
6, Tibetan medicine embodiment 1 of the present invention sees Table 6 to the impact of rat CGRP level.
Table 6 Tibetan medicine embodiment 1 of the present invention is on the impact (x ± s, n=10) of rat CGRP level
Group number of animals dosage (g/kg) CGRP
Blank group 10 342.50 ± 103.62
Positive controls 10 0.6 427.70 ± 183.69
Low dose group 10 1.5 413.72 ± 124.02
Middle dosage group 10 3 522.74 ± 117.32
*
High dose group 10 6 629.21 ± 131.88
* ▲
Illustrate: compare with the blank group:
*P＜0.01; Compare with positive controls:
★ ★P＜0.01; Compare with low dose group:
▲P＜0.05.
As seen from Table 6: 5 groups of SD rats of rat plasma CGRP level determination result were carried out pharmaceutical intervention after 7 days, its Plasma level of CGRP result shows: compare with the blank group, Tibetan medicine embodiment 1 high dose group of the present invention has that the dosage group also is increased significantly (P＜0.05) among remarkable rising (P＜0.01), the Tibetan medicine embodiment 1 of the present invention; Compare with Tibetan medicine embodiment 1 small dose group of the present invention, Tibetan medicine embodiment 1 high dose group of the present invention has remarkable reduction (P＜0.05), positive controls and its difference not statistically significant (P〉0.05).
The clinical observation on the therapeutic effect of [test example 2] Tibetan medicine embodiment 1 treatment mixed hemorrhoid of the present invention:
Physical data: totally 120 examples are observed patients, from May, 2009～2011 year October this gate emergency case, be divided at random two groups by digital method, be respectively 60 examples.
Diagnostic criteria: formulate with reference to State Administration of Traditional Chinese Medicine's " traditional Chinese medical science disease Standardization of diagnosis and curative effect " mixed hemorrhoid diagnosis basis.1. have blood in stool and the swollen thing of podex, rectal tenesmus, foreign body sensation or pain can be arranged.2. can be with merocrine secretion's thing or pruritus.3. swollen thing (also can be superfluous skin under the tooth trace) appears in the up and down same orientation of tooth trace in the anal canal.
Therapeutic Method: 1, matched group: adopt the Fructus Cannabis Bolus treatment, oral, a 9g, 1～2 time on the one.15 is a course for the treatment of.
2, treatment group: adopt Tibetan medicine embodiment 1 of the present invention, oral, a 1.2～2g, 2～3 times on the one.15 is a course for the treatment of.
Clinical efficacy evaluation criteria: formulate with reference to State Administration of Traditional Chinese Medicine's " traditional Chinese medical science disease Standardization of diagnosis and curative effect " mixed hemorrhoid efficacy assessment standard.Cure: transference cure, hemorrhoid disappear.Take a turn for the better: doing well,improving, hemorrhoid are dwindled.Do not heal: symptom, sign are all unchanged.
Healing adding improvement and adding up to total effective rate.
Clinical observation result sees Table 7.
Table 7 liang group Clinical efficacy comparison (example, %)
Group number of cases is cured the more total effective rate that takes a turn for the better not
Treatment group 60 55 32 96.7
Matched group 60 45 69 85.0
Clinical observation result shows: Tibetan medicine embodiment 1 treatment mixed hemorrhoid determined curative effect of the present invention, clinic is promoted the use of, and has certain application prospect.
Claims (1)
1. Tibetan medicine for the treatment of hemorrhoid, it is characterized in that it is comprised of active component or is comprised of active component and pharmaceutically acceptable adjuvant, wherein said active component is to be made by the crude drug of following concrete weight: Fructus Chebulae 300g, HUANGMU cattle urine 500g, Fructus embeliae laetae 110g, Mel 87g, ZUOTAI 3g; The preparation method of wherein said active component comprises the following steps: to take by weighing Fructus Chebulae 300g, HUANGMU cattle urine 500g, Fructus embeliae laetae 110g, Mel 87g, ZUOTAI 3g; HUANGMU cattle urine decocts the elimination slag, and filtrate is condensed into paste, then adds Fructus Chebulae and the suitable quantity of water of enucleation, continues heating and decocts to liquid closely dried, add again refining good Mel, Fructus embeliae laetae powder and ZUOTAI, stir, dry below 60 ℃, be ground into fine powder, mixing is made active component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210342208 CN102836186B (en) | 2012-09-17 | 2012-09-17 | Tibetan medicine for treating haemorrhoids and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210342208 CN102836186B (en) | 2012-09-17 | 2012-09-17 | Tibetan medicine for treating haemorrhoids and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102836186A CN102836186A (en) | 2012-12-26 |
| CN102836186B true CN102836186B (en) | 2013-09-18 |
Family
ID=47364089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210342208 Expired - Fee Related CN102836186B (en) | 2012-09-17 | 2012-09-17 | Tibetan medicine for treating haemorrhoids and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102836186B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150004246A1 (en) * | 2013-06-26 | 2015-01-01 | Yashwant Atbhaiya | Formulation for the Treatment of Diabetes |
| CN103316166B (en) * | 2013-07-17 | 2014-07-16 | 宋永心 | Tibetan medicine for treating hemorrhoids and preparation method thereof |
| CN104306735A (en) * | 2014-10-26 | 2015-01-28 | 青海省通天河藏药制药有限责任公司 | Tibetan medicine for treating haemorrhoids |
| CN104288524A (en) * | 2014-10-26 | 2015-01-21 | 青海省通天河藏药制药有限责任公司 | Method for preparing Tibetan medicine for treating hemorrhoids |
| CN105125882A (en) * | 2015-10-27 | 2015-12-09 | 烟台瑞智生物医药科技有限公司 | Traditional Chinese medicine composition for treating wind-heat stagnation syndrome type anal itching |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1234259A (en) * | 1999-04-30 | 1999-11-10 | 孙富 | Medicine for treating piles |
| CN102370745A (en) * | 2010-08-11 | 2012-03-14 | 郁锋 | Haemorrhoids internal eliminating pill |
-
2012
- 2012-09-17 CN CN 201210342208 patent/CN102836186B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1234259A (en) * | 1999-04-30 | 1999-11-10 | 孙富 | Medicine for treating piles |
| CN102370745A (en) * | 2010-08-11 | 2012-03-14 | 郁锋 | Haemorrhoids internal eliminating pill |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102836186A (en) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102836186B (en) | Tibetan medicine for treating haemorrhoids and preparation method thereof | |
| CN102698097A (en) | Traditional Chinese medicinal composition for treating paradentitis, and formulation and preparation method thereof and toothpaste | |
| CN103989618B (en) | For toothpaste treating gingivitis and preparation method thereof | |
| CN102283909B (en) | Medicament for treating anorectal diseases, adiposity, hyperlipemia and acnes and application thereof | |
| CN101342356B (en) | Traditional Chinese medicine preparation for congestion retardarce, haemal tube obstruction and preparation method thereof | |
| CN101537159B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103316166B (en) | Tibetan medicine for treating hemorrhoids and preparation method thereof | |
| CN107669991A (en) | A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof | |
| CN109464583B (en) | Anti-inflammatory traditional Chinese medicine composition for livestock and preparation method and application thereof | |
| CN101919969B (en) | Traditional Chinese medicine oral liquid preparation for treating hemorrhoids | |
| CN110368445A (en) | A kind of Chinese medicine composition and its preparation method and application for treating psoriasis | |
| CN103285173B (en) | A kind of Chinese medicine treating thrombocytopenic purpura | |
| CN101890100A (en) | Medicament for curing dermatitis and eczema and preparation method thereof | |
| CN105106574A (en) | Application of traditional Chinese medicine combination in treating infertility | |
| CN103705665B (en) | Pharmaceutical composition used for treating thromboangiitis obliterans, and preparation method thereof | |
| CN109172686A (en) | The Chinese medicine composition and its preparation method and application for treating senile skin pruritus | |
| CN109793826A (en) | A kind of Chinese medicine composition for treating fracture of children | |
| CN103191243A (en) | Application of medicament composition composed of coptis chinensis and fructus evodiae and preparation method of medicament composition | |
| CN101391045B (en) | Traditional Chinese medicine compound preparation for treating migraine and general headache and preparation method thereof | |
| CN105194039B (en) | A kind of Chinese medicine composition, the preparation containing the Chinese medicine composition and its preparation and application | |
| CN101264302A (en) | Application of Chinese medicinal composition in preparing medicaments for treating menoxenia and menorrhalgia | |
| CN104288524A (en) | Method for preparing Tibetan medicine for treating hemorrhoids | |
| CN105434808A (en) | Traditional Chinese medicine composition for treating hemorrhoids and preparation method thereof | |
| CN103784881B (en) | A kind of Chinese medicine composition and preparation method thereof for treating dysmenorrhoea | |
| CN105232845A (en) | Chinese medicine composition for treating hemorrhoid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130918 Termination date: 20150917 |
|
| EXPY | Termination of patent right or utility model |